POLE and endometrial cancer: In another early case report, a 57-year-old woman with recurrent, multi-therapy-resistant, stage III endometrial cancer with a POLE P286R mutation showed sustained response to α-PD-1, including regression of abdominal, retroperitoneal and pelvic deposits 7 months after follow-up (102).